News coverage about aTyr Pharma (NASDAQ:LIFE) has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. aTyr Pharma earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.9734917899698 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several equities analysts recently commented on LIFE shares. ValuEngine raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research report on Wednesday, July 12th. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of aTyr Pharma in a research report on Wednesday, May 24th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $3.46.

Shares of aTyr Pharma (LIFE) traded down 1.89% during trading on Friday, reaching $2.60. 40,127 shares of the company traded hands. aTyr Pharma has a 12 month low of $2.10 and a 12 month high of $4.45. The firm’s market capitalization is $61.98 million. The firm has a 50-day moving average price of $3.16 and a 200-day moving average price of $3.34.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.06. Equities research analysts anticipate that aTyr Pharma will post ($2.18) EPS for the current year.

WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/26/atyr-pharma-life-receives-news-sentiment-score-of-0-20.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Insider Buying and Selling by Quarter for aTyr Pharma (NASDAQ:LIFE)

Receive News & Stock Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related stocks with our FREE daily email newsletter.